Given that PARP1 inhibitors have already received FDA approval for treating DNA damage repair-deficient tumors, this study further establishes a solid experimental and theoretical foundation for extending the application of USP1 inhibitors, GCN5 inhibitors, or PARP1 inhibitors to cholangiocarcinoma, potentially paving the way for new combination targeted therapies. This evidence concerns the gene USP1 and cholangiocarcinoma.